MedPath

Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

Not Applicable
Recruiting
Conditions
Metastatic Breast Cancer
Interventions
Behavioral: Lifestyle Intervention
Behavioral: Attention Control
Registration Number
NCT03824145
Lead Sponsor
Medical College of Wisconsin
Brief Summary

This multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. The study will recruit 176 women with MBC in Milwaukee (n=88) and Chicago (n=88).

Detailed Description

Aims/Objectives

Aim 1. To examine the efficacy of the Every Day Counts intervention in producing significant post-intervention changes in multidimensional QOL in women with MBC.

Hypothesis 1: Women randomized to the immediate EDC intervention (n=88) will exhibit greater improvements in multidimensional QOL compared to women randomized to the attention control (n=88).

Aim 2. To investigate the mechanistic effects of the Every Day Counts intervention on body composition, adipokines, serum biomarkers of inflammation and insulin sensitivity.

Hypothesis 2: The EDC intervention leads to improved QOL through mediating factors including body composition, prognostic serum biomarkers of inflammation and/or insulin resistance.

Exploratory Aim 3: To explore if microRNA (miRNA) signatures associated with inflammation and/or Metabolomics are altered with the EDC intervention.

Hypothesis: miRNAs identified in our pilot study (miR-10a-5p, miR-205-5p, and miR-211-5p) that regulate inflammation and/or Metabolomics will be related to QOL improvements and can identify women more likely to respond to lifestyle changes.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
176
Inclusion Criteria
  • Adult (≥ 18 years), female

  • Confirmed Metastatic Breast Cancer

  • Patients clinically stable with treated brain metastases are eligible

  • Written documentation from their oncologist permitting study participation

  • Determined to be "clinically stable" by their medical oncologist (i.e., no unintentional weight loss, no new symptoms or change in performance status for the past 4 weeks, no clinical [including laboratory] or radiologic evidence of disease progression, no recent or planned change in anti-neoplastic therapies, no reports of severe pain [≥ Grade 3 per the NCI CTCAE)

  • Life expectancy >6 months

    -Written documentation from their oncologist permitting study participation

  • Access to a mobile phone

  • Understand/speak English fluently.

  • Non-adherence to ACS nutritional or PA guidelines for cancer survivors as documented by questionnaire.

Exclusion Criteria
  • Does not meet the above criteria.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Immediate InterventionLifestyle InterventionThe experimental arm will receive a 16-week lifestyle intervention that promotes nutritional and physical activity changes concordant with those contained in the ACS nutrition and physical activity guidelines for cancer survivors. The 16-week intervention includes: 1) a curriculum binder covering weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 16-weeks, with in-person or virtual supervised exercise sessions and telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to cooking classes emphasizing plant-based eating.
Attention ControlAttention ControlThe attention control participants will receive a home/work organization intervention: * Participants will receive a book with overview of home/work organization program with 16 weekly topics with an overview of each chapter. * Virtual or weekly phone calls- with a home organization coach with standard prompts. * Text messages supporting home/work organization.
Primary Outcome Measures
NameTimeMethod
Intervention retention8 months

Number of women who complete the 8-month data collection

Body compositionchange from baseline to 8 months

Ratio of percent lean mass to percent adiposity as measured by DEXA. More lean mass and less adiposity is favorable.

Intervention adherence4 months

Number of lifestyle coaching sessions completed out of a possible total of 16 sessions

Change in Quality of Lifechange from baseline to 8 months

Patient reported outcomes as measured by Functional Assessment of Cancer Therapy-Measured by the Functional Assessment of Cancer Therapies Breast, Fatigue and Endocrine Symptoms (FACT-B, F and ES). The FACT-G is the overarching measure with a score range of 0-108; FACT-B (breast) subscale score range is 0-40; FACT-ES (endocrine symptoms) subscale score range is 0-76; FACT-F (fatigue) subscale is 0-52. Higher scores are better.

Secondary Outcome Measures
NameTimeMethod
Serum Biomarker Adipokine Dysregulation - AdiponectinChange from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits

Serum Biomarker Insulin Resistance- C-PeptideChange from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits

Serum Biomarker Inflammation - Tumor Necrosis Factor - alphaChange from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits

Serum Biomarker Inflammation - C-Reactive ProteinChange from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits

Serum Biomarker Insulin Resistance- GlucoseChange from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits

Serum Biomarker Adipokine Dysregulation - LeptinChange from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits

Serum Biomarker Insulin Resistance - InsulinChange from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits

Serum Biomarker Inflammation - Interleukin 6Change from baseline to 4 month

Analyzed by EVE technologies using standard ELISA kits

Trial Locations

Locations (2)

Loyola University

🇺🇸

Maywood, Illinois, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath